Literature DB >> 19822290

Multimodality strategies in malignant pleural mesothelioma.

Walter Weder1, Isabelle Opitz, Rolf Stahel.   

Abstract

Over the last decade, several improvements have been made in the diagnosis and treatment of malignant pleural mesothelioma, including better understanding of tumor biology, availability of more potent chemotherapeutic drugs, improved surgical management, and optimized multidisciplinary therapy. Radical tumor resection by means of extrapleural pneumonectomy (EPP) is now feasible with acceptable morbidity and mortality, even after neoadjuvant chemotherapy, if performed in specialized centers. To date, the best survival data have been reported after multimodality treatment strategies that include surgical resection. In this article, we discuss several strategies that involve EPP or pleurectomy/decortication in combination with various adjuvant and neoadjuvant therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19822290     DOI: 10.1053/j.semtcvs.2009.07.004

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  9 in total

1.  SEOM guidelines for the treatment of malignant pleural mesothelioma.

Authors:  Pilar Lianes; Jordi Remon; Isabel Bover; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

2.  An IR Navigation System for Pleural PDT.

Authors:  Timothy C Zhu; Xing Liang; Michele M Kim; Jarod C Finlay; Andreea Dimofte; Carmen Rodriguez; Charles B Simone; Joseph S Friedberg; Keith A Cengel
Journal:  Front Phys       Date:  2015-03

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 4.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Authors:  Kevin Hollevoet; Johannes B Reitsma; Jenette Creaney; Bogdan D Grigoriu; Bruce W Robinson; Arnaud Scherpereel; Alfonso Cristaudo; Harvey I Pass; Kristiaan Nackaerts; José A Rodríguez Portal; Joachim Schneider; Thomas Muley; Francesca Di Serio; Paul Baas; Marco Tomasetti; Alex J Rai; Jan P van Meerbeeck
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

5.  The evolution of multimodality therapy for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Curr Treat Options Oncol       Date:  2011-06

6.  Bilateral dissemination of malignant pleural mesothelioma via iatrogenic buffalo chest: a rare route of disease progression.

Authors:  Kohei Ikezoe; Eisaku Tanaka; Kiminobu Tanizawa; Seishu Hashimoto; Toru Shindo; Satoshi Noma; Yoichiro Kobashi; Yoshio Taguchi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-05-12

7.  Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.

Authors:  Petra C Schuberth; Christian Hagedorn; Shawn M Jensen; Pratiksha Gulati; Maries van den Broek; Axel Mischo; Alex Soltermann; Astrid Jüngel; Osiris Marroquin Belaunzaran; Rolf Stahel; Christoph Renner; Ulf Petrausch
Journal:  J Transl Med       Date:  2013-08-12       Impact factor: 5.531

8.  Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).

Authors:  Ulf Petrausch; Petra C Schuberth; Christian Hagedorn; Alex Soltermann; Sandra Tomaszek; Rolf Stahel; Walter Weder; Christoph Renner
Journal:  BMC Cancer       Date:  2012-12-22       Impact factor: 4.430

9.  Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.

Authors:  Rea Federico; Favaretto Adolfo; Marulli Giuseppe; Spaggiari Lorenzo; DePas Tommaso Martino; Ceribelli Anna; Paccagnella Adriano; Crivellari Gino; Russo Francesca; Ceccarelli Matteo; Kazeem Gbenga; Marchi Paolo; Facciolo Francesco
Journal:  BMC Cancer       Date:  2013-01-16       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.